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Background and Aims: Congenital extrahepatic portosystemic shunt (CEPS) or Abernethy 
malformation is a rare condition in which splanchnic venous blood bypasses the liver draining directly 
into systemic circulation through a congenital shunt. Patients may develop hepatic encephalopathy 
(HE), pulmonary hypertension (PaHT) or liver tumors, among other complications. However, the 
actual incidence of such complications is unknown mainly due to the lack of a protocolized approach 
to these patients. This study characterizes the clinical manifestations and outcome of a large cohort of 
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Methods: Observational multicenter international study.  
Results: Sixty-six patients were included, median age at the end of follow-up was 30 years. Nineteen 
patients (28%) presented HE. Ten, 20 and 30 year HE incidence rate were 13, 24 and 28%, 
respectively. No clinical factors predicted HE. 
 Twenty-five patients had benign nodular lesions. Ten patients developed adenomas (median age: 18 
years) and another 8 developed HCC (median age: 39 years). 
Out of 10 patients with dyspnea, PaHT was diagnosed in 8 and hepatopulmonary syndrome in 2. 
Pulmonary complications were only screened for in 19 asymptomatic patients and PaHT was 
identified in 2.   
Six patients underwent liver transplantation (LT) for HCC or adenoma. Shunt closure was performed 
in 15 patients with improvement/stability/cure of CEPS manifestations.  
Conclusion: CEPS patients may develop severe complications. Screening for asymptomatic 
complications and close surveillance is needed. Shunt closure should be considered both as a 
therapeutic and prophylactic approach. 
 
Introduction 
Congenital extrahepatic portosystemic shunts (CEPS) are a rare condition in which most of 
the intestinal and splenic venous blood bypasses the portal vein and the liver, draining directly into 
systemic veins through abnormal communications. Anatomically, CEPS has been classified in two 
types (1)
,
(2). Type I CEPS is characterized by the absence of intrahepatic portal vein branches and 
an end-to-side portocaval shunt, while in type II CEPS the intrahepatic veins are hypoplastic but 
patent and a side-to side shunt diverts blood from the portal vein to the inferior vena cava. Type I 
CEPS can be further classified into type Ia, when the superior mesenteric and splenic vein drain 
separately into inferior cava veins (IVC), and type Ib, when these veins form a common trunk before 
draining into the IVC.  
Recently, more detailed anatomical subclassifications (3)
,
(4) have been described, correlating 
the anatomy of the shunt to the surgical approach required for its closure(4)
,
(5). It has also been 
stated that, to accurately assess the patency of intrahepatic veins, an angiography with occlusion of 
the shunt should be performed, to distinguish if the assumed absence of intrahepatic veins could in 
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CEPS is usually associated with congenital anomalies, the most frequent being cardiac 










In countries routinely performing neonatal screening for hereditary galactosemia, it has been 
estimated that the incidence of congenital portosystemic shunts is around 1 in 30,000 births (10)
,
(11) 
(high levels of galactose can be found in newborns with congenital portosystemic shunts because 
galactose bypasses the liver). However, the usefulness of galactosemia screening to infer CEPS 
prevalence is debatable because other circumstances could cause false positive results, 
galactosemia levels cannot differentiate intra and extrahepatic shunts and, finally, it may 
underestimate its real prevalence since not all patients with CEPS harbor hypergalactosemia.   
To our knowledge, less than 300 cases of CEPS have been reported in the literature. The 





(13), hepatopulmonar syndrome (HPS) and pulmonary arterial 
hypertension (PaHT)(14–16).Nodular liver lesions are frequent in patients with CEPS and although 
most of these nodules are benign, hepatocellular carcinomas and adenomas, among other neoplastic 
lesions, have been reported (17)
, ,
(18). However, the vast majority of these publications are single 
case reports providing only a cross-sectional description without follow-up. Although some series 






(20) most mix patients with CEPS and intrahepatic congenital 
portosystemic shunts (IPSS). The natural history of these two entities might be different, being IPSS 
more frequently asymptomatic and undergoing spontaneous closure during infancy (<2 years old). 
Moreover, there are no reports of malignant liver tumors in IPSS (13)
,
(21). For these reasons, our 
study focuses on extrahepatic shunts only.  
Because knowledge on the natural history and outcome of patients with Abernethy 
malformation are mainly based on paediatric series, there are no formal recommendations on the 
evaluation and management of adult patients with CEPS. Our study describes the clinical 
manifestations, natural history, current diagnostic procedures, treatments applied and outcome of a 
large cohort of patients with CEPS with the aim of proposing a guide to homogenously approach 
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Patients and Methods 
This is a multicenter observational retrospective international study performed in the setting of 
VALDIG Group (Vascular Liver Disease Interest Group) and the REHEVASC group (Registro Español 
de Enfermedades Vasculares Hepáticas).The 23 participating hospitals are listed in Annex 1. The 
local ethical committees of each hospital approved the study in accordance with the International 
Guideline for Ethical Review of Epidemiological Studies and principles of the Declaration of Helsinki.  
 
Patients and study design 
Every patient diagnosed in any of the participating hospitals was considered for inclusion if 
they had at least one imaging study demonstrating the presence of CEPS.  
Demographic, clinical and imaging data at diagnosis were retrospectively recorded as well as 
follow-up data and the therapeutic approaches in a specifically designed case report form. HE, PaHT, 
HPS, HCC and adenoma were considered major CEPS complications.  
 
Results 
 Since June 1989 until May 2018, 76 eligible patients were identified at the 23 participating 
centers. Ten of these patients were excluded from the study: 3 because CEPS diagnosis was not 
conclusive, 3 because they presented an intrahepatic portosystemic shunt instead of CEPS and 4 
because they had concomitant cirrhosis at diagnosis making it difficult to establish whether symptoms 
were due to cirrhosis or to CEPS. Finally, 66 patients with Abernethy malformation were included. Of 
those, 10 patients had been previously reported as isolated case reports or as part of small series 
(4,22–24). Follow-up of these patients has been updated for the current study.  Out of the 66 patients, 
35 (53%) were men. At diagnosis, patients had a median age of 21 years (range: 0-66 years). The 
median follow up was of 5.2 years (range: 0-22) and the median age at the end of follow-up was 30 
years (range: 0-68 years). Table 1 shows baseline characteristics of patients at diagnosis and 
Supplementary Figure 1 shows the distribution of age at diagnosis. Table 2 summarizes the findings 
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Diagnosis 
 All patients were incidentally diagnosed through imaging tests. In 13 of the 66 patients 
(19.7%), the imaging test was performed because patients already presented with symptoms 
potentially attributable to CEPS: HE in 6 cases and dyspnea in 7 cases. In the remaining 53 patients 
(80.3%), the imaging study was performed for other different reasons (Table 1). 
There were no significant differences in the age at diagnosis between patients with symptoms at 
diagnosis (22 years, range: 2–64,) or without symptoms (24 years, range: 0-66) (p = 0.57).  
 Imaging studies demonstrating the presence of CEPS were a Doppler ultrasound in 3 patients 
(4.5%), CT scan in 36 patients (54.5%), MRI in 10 patients (15.2%) and both CT and MRI in 17 
patients (25.8%). Based on these imaging studies, type I CEPS was identified in 39 patients (59%, 
type Ia and type Ib in 7 and 32 patients, respectively) and type II in the remaining 27 patients (41%). 
There were no significant differences in sex, association to other congenital malformations or age at 
diagnosis between type I and II CEPS. Remarkably, 8 patients classified as type I CEPS at CT scan 
were shown to actually have intrahepatic portal vein inflow when further studied with an endovascular 
shunt occlusion test. This occlusion test was not performed in all patients, making it impossible to rule 
out that other patients previously considered as type I had indeed type II CEPS with residual 
hypoplastic portal branches.  
 Although not necessary for diagnosis, in 19 patients (29%) a liver biopsy was performed. Liver 
biopsies were considered normal in 3 patients while the remaining 16 patients presented structural 
changes in different degrees: in 9 patients there were absent or hypoplastic portal vein branches in 
the portal tracts, combined in some cases with congestive sinusoids and large arterial branches; 8 
patients presented low degree of periportal fibrosis and 3 patients presented moderate steatosis. 
Liver blood test at diagnosis showed a preserved liver function with a median albumin of 37.5 mg/dL 
(range 30–46mg/dL), prothrombin ratio of 80% (range: 60–100%) and bilirubin of 1.1 mg/dL (range: 
0.17 – 4mg/dL).  
Associated Congenital malformations 
 Twenty-nine patients (44%) presented one or multiple associated malformations 
(Supplementary table 1). Cardiac defects were the most common defects (n=20), followed by 
musculoskeletal abnormalities (n=9).  
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 Nineteen patients (29%) developed hepatic encephalopathy (HE) at some time during the 
study. The median age at HE diagnosis was 12 years (range: 5-65). HE was already present at 
diagnosis in 14 patients while the other 5 patients developed HE during follow-up. 
Different patterns of HE were observed with a clear preponderance of chronic HE: 14 patients had 
persistent HE with permanent cognitive impairment; 2 patients had recurrent HE and 3 patients had 
episodic HE. In most patients the episodes of HE were of moderate intensity (grade I in 11 patients 
and grade II in 7 according to West-Haven criteria) and only one patient had grade III-IV HE. 
Presence of minimal HE was tested only in 2 asymptomatic patients with the critical flicker frequency 
test (CFF) and psychometric hepatic encephalopathy score (PHES) tests and one of them was 
classified as having minimal HE. 
The cumulative probability of HE at 10, 20 and 30 years was 13%, 24% and 28%. (Figure 1a).  
Sixteen out of the 19 patients with HE (84%) presented with HE before the age of 25 while the 
remaining 3 patients had HE after the age of 50. These 3 patients represent 27% of all patients with 
an age above 50. There were no significant differences in the incidence of HE between patients with 
type I or type II CEPS (Figure 1b, p=0.57). In addition, there were no significant associations between 
HE development and sex, presence of associated malformations, parameters assessing liver function 
or presence of other CEPS manifestations.   
Brain MRI was performed in 19 of the 66 patients (29%). In 10 of them MRI was performed after 
developing HE and in 9 cases in the absence of previous HE (Supplementary Table 2). Presence of 
high signal intensity in the globus pallidum (GP) on T1-weighted images was more frequent in 
patients with HE (70% vs. 30%, p=0.17). Among the 3 patients without HE but with GP high intensity 
at MRI, 1 of them developed HE 4 years later, while none of the 6 without neither HE nor GP high 
intensity presented clinical HE after a median follow-up of 20 years (range 1.5–35). No relation was 
detected between the grade or pattern of HE and the presence/absence of high GP intensity.  
Venous serum ammonia levels determined in 20 patients at diagnosis were high in almost all of them 
(median 89.5 µmol/L range: 48-273, normal value <50µmol/L). Eight patients had already developed 
HE at the moment of the test, but no significant differences in serum ammonia levels were found with 
those of the remaining 12 patients who had not developed HE: 106 µmol/L (range: 48-273) for HE vs. 
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and other clinical characteristics of patients such as CEPS type, age at testing, sex or brain MRI 
findings.  
Thirteen patients had additional serum ammonia tests during follow-up (after liver transplant in 1, 
shunt closure in 6 and after medical treatment of HE in 6), showing a significant reduction in the levels 
in all but one patient (median ammonia levels 51µmol/L, range 23-95).  
Liver Nodules 
 All patients were screened for nodules. In 43 of the 66 patients (65%) liver nodules were 
identified. Out of the 43 patients with nodules, 9 patients (21%) had a single nodule, 24 patients 
(55%) had 2 to 10 nodules, 5 patients (12%) had 10 to 20 nodules and 5 patients had more than 20.  
The nature of liver nodules was established by biopsy in 25 patients (58%) and through imaging 
characterization in the remaining 18 patients. Supplementary Table 3 shows liver nodules 
classification in patients with and without biopsy.  
Overall, 18 patients had neoplastic lesions (8 HCC and 10 adenomas) and 25 patients had non-
neoplastic nodules (nodular regenerative hyperplasia in 7, focal nodular hyperplasia in 12 and non-
specific in 6). HCC was diagnosed at a median age of 39 years (range: 32-53) and had a median size 
of 94 mm (range: 11-160 mm); 4 of them were identified at CEPS diagnosis while the other 4 were 
identified after a median of 9 years of follow-up (range 4-16). Adenomas were diagnosed at a median 
age of 18 years (range: 4-46) and had a median size of 76 mm (range: 11-180). Benign nodules were 
identified at a median age of 20 years (range: 7-52) and had a median size of 36 mm (range: 10-
100mm). 
AFP levels were evaluated in 39 patients, including all patients with HCC. It was found that AFP was 
elevated only in 5 patients, 4 of whom presented HCC (median 1459.5 U/ml, range 74-7627). The 
remaining 4 patients with HCC had normal levels of AFP. The only patient with high AFP without HCC 
remained without evidence of HCC until the end of his follow-up 2 years later. All cases of HCC were 
identified in patients with type I CEPS (type I n=8, type II n= 0; p = 0.03). Seven out of the 8 patients 
with HCC were male (p = 0.05), corresponding to a cumulative incidence of HCC of 40% in males with 
type I CEPS older than 30 years. Regarding adenomas, there were no significant differences in their 
distribution in relation to CEPS type (type I n= 7, type II n=3; p = 0.5). All 10 patients with adenoma 
were female (male n= 0, female n= 10; p = 0.001). Thus, in this cohort, 33% of female patients 
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Twenty of the 25 patients with benign nodules had at least one imaging study during follow-up 
(median time from first to last imaging study: 9.8 years, range: 0.3-20years). In most cases, the size 
and number of nodules remained stable. However, a small increase in size was observed in 3 
patients (median increase 13 mm, range: 5-30 mm) and additional nodules appeared during follow-up 
in 4 patients.   
Pulmonary arterial hypertension (PaHT) and hepatopulmonary syndrome (HPS) 
Ten patients had dyspnea at a median age of 18 years (range: 2-42years). Pulmonary arterial 
hypertension was diagnosed in 8 of them (in 6 it was the main symptom leading to CEPS diagnosis, 
with a mean pulmonary arterial pressure of 46.5mmHg ± 5.3), and hepatopulmonary syndrome in the 
other 2 (severe in both of them, with hypoxemia PaO2 <50mmHg requiring domiciliary oxygen). 
Pulmonary arterial circulation was evaluated with echocardiography (n=18) and/or Swan-Ganz right 
heart catheterization (n=3) in 19 of 37 (51%) asymptomatic patients, revealing PaHT in two of them 
(ages of 1 and 10 years, respectively). Sex, presence of other congenital malformations or cardiac 
defects, type of CEPS, development of HE or nodules was not associated with the presence of PaHT 
or HPS.  
The cumulative incidence of at least one major CEPS complication (HE, PaHT, HPS, HCC and 
adenoma) at 20, 30 and 40 years was 35%, 45% and 58%, respectively (Figure 2).  
 
Treatment and Outcome 
Three out of the 19 patients with HE presented subjective improvement with lactulose and rifaximin, 
while the other 16 presented persistent or recurrent HE despite receiving medical treatment. Four of 
the patients with persistent HE underwent shunt closure resulting in cognitive improvement and a 
decrease in ammonia blood level in all of them. One of them had a brain MRI 2 years after shunt 
closure showing a reduction in GP hyperintensity. Two of the patients with HE underwent liver 
transplantation (one because he presented HCC and the other adenoma), and they evolved with 
resolution of HE.  
Seven of the 10 patients with PaHT remained stable with specific medical treatment (median follow-
up 7.5 years, range 0-37). The other 3 patients underwent shunt closure, observing a clear clinical 
improvement in 2 patients (in one confirmed also by cardiopulmonary catheterization) and making it 
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closure and the one in whom there was no discernible improvement were as follows: younger age (23 
and 24 years vs 34 years), lower mean pulmonary pressure (44 and 49mmHg vs 51mmHg) and 
shorter duration since diagnosis of PaHT (2 and 16 years vs 29 years) in those that improved. 
Two patients with HPS underwent shunt closure, both at the age of 41, which was followed by 
resolution of hypoxemia and dyspnea 1 month and 1 year after the procedure, respectively. 
 
Among the 8 patients with HCC, one patient presented an acute hemoperitoneum and died shortly 
afterwards. Six patients were submitted to surgical hepatectomy: 3 showed no HCC recurrence after 
a median follow-up of 36 months (range 4-48) after surgery, while the other 3 developed HCC 
recurrence after a median of 44 months (range: 38-48), one of them eventually dying. One patient 
with concomitant HE underwent liver transplantation without further complications and was free of 
disease after 6 months of follow-up.   
Out of 10 patients with adenomas, 3 were treated with surgical hepatectomy and had no 
complications after a median follow-up of 12 months (range: 3-84 months). Five were transplanted 
(one of them with concomitant HE) and, among them, one died 5 months later due to septic 
complications. One patient underwent shunt closure but no changes in adenoma size (120 mm) were 
observed after 2 years of follow-up. An additional patient with a small adenoma (11 mm) was 
managed conservatively and remained stable after 4 years of follow-up. 
 
In 5 asymptomatic patients shunt closure was performed as a preemptive measure at a median age 
of 20 years old (range: 5-31). No complications were registered until the end of their follow-up 
(median of 5.5 years after shunt closure, range: 1-12years). Interestingly, 4 of these 5 patients 
presented benign nodules and all of them experienced a decrease in their size and/or number. 
Overall, 15 patients (23%) underwent shunt closure, their main features according to the type of 
CEPS are summarized in Table 3. The main indication was chronic HE in 4 patients, PaHT in 3 
patients, HPS in 2 patients, presence of a large adenoma in 1 patient and preemptive in 5 patients. 
Shunt closure was performed at a median age of 17.5 years (range: 3-41) using a surgical ligation in 
11 patients and a percutaneous endovascular technique in the remaining 4 patients. The election of 
surgical vs endovascular approach was guided mainly by the size of the shunt. Eight patients had 
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the intrahepatic portal vein branches were identified when a shunt occlusion was performed, in 
contrast with the lack of connection between the portal venous axis and the intrahepatic circulation 
described by the conventional imaging studies.  
In 6 patients the procedure was done in 2 steps to facilitate progressive redirection of portal blood 
flow to the liver. Remarkably, in one patient with type I CEPS the occlusion test showed a marked 
increase in portal pressure without adequate drainage, making a TIPS (transjugular intrahepatic 
portosystemic shunt) placement deemed to decompress the portal venous system before completing 
shunt closure (Supplementary Figure 2). Probably because of these safety precautions, only one of 
the 15 patients with shunt closure presented a thrombosis of the mesenteric and splenic vein, a 
complication directly attributable to the shunt closure procedure.. This patient was on anticoagulation 
during 1 year but no regression of the thrombus was achieved. In the other 14 patients there were 
neither portal hypertension related complications nor signs of bowel ischemia. None of the 15 patients 
developed new CEPS complications after a median of 2.5 years of follow-up after shunt closure 
(range: 0-12 years). In 4 of the 15 patients a median increase of 428cm
3
 (range 179-598) in liver 
volume was reported. 
There were 21 patients (32%) without major complications of CEPS that remained asymptomatic 
without being submitted to any intervention until the end of their follow-up at a median age of 33 years 
(range: 5-67).  
 
Discussion  
 CEPS are an infrequent malformation characterized by the presence of a communication 
between the portal vein (or one of its afferent veins) and the inferior cava vein diverting the blood flow 
to the systemic circulation. These alterations in the splanchnic circulation produce hemodynamic and 
physiological changes that lead to severe complications. Nevertheless, knowledge about CEPS is 
scarce as the low incidence of this malformation has prevented the realization of large studies. In the 
current study, we have retrospectively enrolled 66 patients with congenital extrahepatic portosystemic 
shunts, thus presenting the largest series of patients with CEPS up to now with a long follow-up with 
more than 80% of patients achieving adulthood. This has allowed us to further characterize the 
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out the highly variable approaches among the different centers. Based both on our results and on 
previous reports, we suggest a work-up for CEPS in an attempt to homogenize its management.  
 The results of the current study show that patients with CEPS can remain asymptomatic until 
late in the disease and be undiagnosed until an advanced age. This is in contrast with previous case 
reports and series where approximately 75% of CEPS were diagnosed during childhood (3)(16) 
(19)(25)(26). However, because most of the participating centers take care of adult patients, a bias 
evaluating the age of our patients at diagnosis cannot be discarded.  
 In the current cohort, CEPS proved to be a severe and life threatening condition in many 
patients (68% of patients included in the study developed severe complications related to CEPS). It is 
important to underline that we may be underestimating the real incidence of CEPS complications as 
some of them can be present but asymptomatic and remain undiagnosed if not specifically screened 
for. Similarly, however, as data from a systematic population screening are not available, we also 
cannot estimate the burden of uncomplicated patients with CEPS that remain undiagnosed and that 
may never develop symptoms. 
   In agreement with previous small series (27), HE was the main complication in our cohort 
affecting more than one every four patients. This is highly relevant since even mild and minimal HE 
have proven to diminish quality of life.  The present study was unable to identify any clinical or 
biochemical parameter (including ammonia levels) able to predict HE development. Out of the 47 
patients without overt HE, minimal HE was only evaluated in 2 patients. Minimal HE could present in 
atypical forms and be difficult to detect if not suspected, especially in patients with CEPS that 
frequently present associated congenital malformations and intellectual disabilities. Thus, future 
studies systematically evaluating the presence of minimal HE are warranted.    
  It is possible, however, that the finding of high GP intensity in brain MRI in patients without HE 
could identify patients at a higher risk of developing HE or having minimal HE. Nevertheless, our data 
also show that the lack of high GP intensity in brain MRI cannot confidently exclude the presence of 
HE in equivocal cases because this alteration was absent in 20% of cases with clear overt HE. 
Unfortunately, the number of patients without HE studied with brain MRI was very small, precluding 
any definitive conclusion. It will be of great interest to include brain MRI in the work-up of newly 
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Our study also suggests that HE may be bimodal, with most patients developing HE before the age of 
25 but with a second rise in new-onset HE after the age of 50. Although we do not have an 
explanation for this finding, we can speculate that loss of brain reserve associated with aging may 
facilitate the revelation of HE (28).  
 Liver nodules have been previously described in as much as 40% of the reported patients 
with CEPS, being mainly focal nodular hyperplasia and regenerative nodular hyperplasia (70%). 
Hepatocellular carcinoma (20%) and adenomas (10%) have been described in a lower proportion 





(27), reaching 65% of patients. More importantly, a relevant and higher proportion of 
patients than previously described in the literature had adenomas and HCC, probably in the context of 
better imaging accuracy in the recent years and also in relation to the older age of our patients. In this 
regard, even though pediatric patients with CEPS have been described to develop HCC (29), in our 
cohort HCC was a late complication appearing after the age of 30.   
 Previous observations suggested that the development of liver nodules (regardless of their 
nature) is more frequent in type I CEPS than in type II CEPS (17)
, 
(18). In our cohort this was the case 
only for HCC, which appeared almost exclusively in type I CEPS, probably in the setting of more 
severe alterations in liver perfusion and excessive arterialization due to the lack of portal blood flow 
(30)
,
. In our series HCCs were seen almost exclusively in men, while adenomas were observed only 
in women. This sex predilection is similar to that observed in general population and does not have a 
clear explanation. However, evidence suggests that HCC is an androgen sensitive tumor (31) and 
that the increased estrogen levels of females may enhance the risk of developing benign liver tumors 
(32). Nevertheless, it should be noted that adenomas have been also reported in males with CEPS in 
the literature (19).  These data suggest the need of performing a careful and periodic screening for 
liver nodules in patients with CEPS and therefore it would seem sensible to adopt the cirrhosis 
strategy of HCC surveillance every six months.  
 Patients with CEPS have been reported to develop severe pulmonary complications such as 
PaHT (19)
,
(33). and, less frequently, hepatopulmonary syndrome (27)
, 
(14). The development of HPS 
and PaHT could be in relation to intestinal vasoactive mediators (14,15,34)
 
that, having bypassed the 
liver and not being properly metabolized, reached the pulmonary vascular bed inducing a long-
standing pulmonary vasoconstriction in the case of PAHT (15,16)
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vasodilation in the case of HPS. Our study confirms that PaHT is a significant problem in patients with 
CEPS causing symptomatic dyspnea in 80% of cases. Moreover, in this cohort 11% of asymptomatic 
patients also presented PaHT when specifically screened for it. Because PaHT was identified at a 
wide range of age, screening for PaHT may be worthy to be repeated during follow-up. Because 
performing periodic cardiac catheterization can be inconvenient, it seems reasonable to recommend 
using echocardiogram for follow-up PaHT screening. The study should be subsequently completed 
with cardiopulmonary catheterization if indirect signs of PaHT were found. Hepatopulmonary 
syndrome appears to be less frequent than PaHT, with prevalence in our study of 3%. However, as 
mild forms of HPS might be asymptomatic and an exhaustive pulmonary study was not performed in 
all the patients of our cohort, its real prevalence cannot be estimated. It would be advisable to perform 
a baseline exhaustive screening of pulmonary complications and, afterwards, periodic screening with 
transcutaneous oxygen saturation measurements could be helpful for early detection of its 
appearance during follow-up. 
 
 Fifteen patients (23%) were submitted to shunt closure, at a median age of 17 years, but as 
young as at 3 years and as late as at 41 years. It is important to remark that shunt closure restoring 
portal blood flow to the liver was possible even in patients with type I CEPS. This reinforces the theory 
that the assessment of intrahepatic portal veins patency based only in CT-Scan or MRI without 
performing an occlusion test might be misleading because residual hypoplastic veins might be only 









(36). The current study confirms this relevant finding given that in all type I CEPS 
patients that underwent an occlusion test, remnants of the intrahepatic portal vein branches were 
identified. Establishing confidently the presence or absence of intrahepatic veins is highly relevant 
when evaluating possible therapeutic options, as classically type I patients could only be treated with 
liver transplantation. Nevertheless, the type I and II CEPS classification is still useful because, even if 
the intrahepatic portal vein branches may be also present in type I CEPS, they are hypoplastic and 
leading less, if any, flow to the liver (3)
,
, which could have pathophysiological consequences like more 













This article is protected by copyright. All rights reserved. 
 Shunt closure was always performed after checking that the procedure was associated with 
an adequate redirection of portal blood flow to the liver, usually requiring a two-step intervention 
promoting the stenosis of the portal-collateral circulation with the ensuing increase in the portal 
system pressure leading to the reopening of the hypoplastic portal branches. Some authors have 
suggested that prophylactic anticoagulation could also be useful to prevent thrombosis after shunt 
closure (19,20). Our results coincide with previous reports (5)
,
(16) suggesting that shunt closure has a 
huge efficacy managing most CEPS complications and, most interestingly, preventing its appearance. 
Therefore, shunt closure must be always considered in symptomatic patients and should also be 
considered as a prophylactic treatment early in the evolution of the disease to prevent the 
development of severe complications. Nevertheless, it cannot be assured that the risk of 
complications completely disappears with the occlusion of the shunt, and thus HCC surveillance 
should still be performed until more data are available.  
 
In the current cohort, shunt closure was especially useful in improving HE but was less effective in 
patients with long-standing and severe PaHT, probably because the highest the pressure, the less 
improvement after closure can be expected. Although the only patient with adenoma in our cohort did 
not improve after shunt closure, partial adenoma regression after shunt closure  has been reported 
(19).   
The present study shows that the current diagnostic and therapeutic approach of CEPS is highly 
variable depending on each center policy. We consider that consensus guidelines would improve the 
knowledge of the disease and the management of these patients. Thus, based on the results of our 
cooperative study, in Figure 3 we propose a management algorithm for all patients with CEPS. 
 
Conclusion  
This is the largest CEPS cohort until now and the only one in which most patients have reached 
adulthood at the end of follow-up, which could explain some of the clinical differences found in 
comparison with previous reports. CEPS patients may develop significant morbidity and life-
threatening complications. Therefore, screening for asymptomatic complications and close 
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        Table 1. Baseline characteristics (n = 66) N % 
   Sex (male)   35 53 
   Reason Diagnosis     
         CEPS Symptoms:   13 19.7 
   
 
HE 6 9.1 
     Dyspnea 7 10.6 
       Imaging study for:       
   
 
Abnormal liver test 16 24.2 
   
 
Abdominal pain  10 15.2 
   
 
Other malformations 7 10.6 
   
 
Prenatal US 2 3 
     Others 18 27.3 
    Type I CEPS   
Type Ia 
39 59 
   
 
7   
     Type Ib 32   
    Type II CEPS   27 41 
       Median Range, (SD) 
   Age at diagnosis   21 0-66,(16.7) 
    ALT U/L   36 10-103, (21.1) 
    AST U/L   38 11-93, (17.9) 
    GGT U/L   79 15-370, (95.1) 
    Bilirubin mg/dL 1.1 0.1-4, (0.94) 
    Ammonia µmol/L* 101 48-273, (49.7) 
    Prothrombin ratio 80 60-100, (13) 
   * Ammonia levels were determined in 20 patients    
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Type I CEPS Shunt closure 
HE: n=19 (29%) 12 (5-65) 9 (47%) 12 (63%) 4 
PaHT: n = 10 (15%) 20 (2 -42) 6 (60%) 6 (60%) 3 
HPS:  n = 2 (3%) 41 (41-41) 1 (50%) 0 2 
HCC: n = 8 (12%) 39 (32-53) 7 (87%) 8 (100%) 0 
Adenoma: (n= 10, 15%) 18 (4-46) 0 7 (70%) 1 
No main complications 
(n= 21, 32%) 
30 (0-67)* 16 (76%) 13 (62%) 5 
 




 Type I CEPS Type II CEPS 
Shunt closure 8 7 
Technique Surgical  5 6 
Endovascular 3 1 
Steps One step 5 4 
Two steps 3 3 
Indication PaHT 2 Resolution in 1  1 Resolution 
HPS 0 2 Resolution  
HE 4 Improvement in all  0 
Adenoma 1 No changes 0 
Prophylactic 1 No complications  4 No complications  
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